πŸ‡ΊπŸ‡Έ FDA
Patent

US 8106160

N-terminal modified interferon-alpha

granted A61KA61K38/00A61P

Quick answer

US patent 8106160 (N-terminal modified interferon-alpha) held by PHARMAESSENTIA CORPORATION expires Mon Jan 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PHARMAESSENTIA CORPORATION
Grant date
Tue Jan 31 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K38/00, A61P, A61P31/12